Mutation status and surgical selection
暂无分享,去创建一个
[1] J. Spicer,et al. Anatomical Resections Improve Survival Following Lung Metastasectomy of Colorectal Cancer Harboring KRAS Mutations. , 2019, Annals of surgery.
[2] V. Whitehall,et al. How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications , 2018, Gastroenterology research and practice.
[3] J. Vauthey,et al. ASO Author Reflections: RAS Mutations in Metastatic Colorectal Cancer , 2018, Annals of Surgical Oncology.
[4] Yuhree Kim,et al. Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases , 2018, The British journal of surgery.
[5] P. Lønning,et al. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer , 2018, JAMA surgery.
[6] J. Vauthey,et al. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases , 2018, Annals of Surgical Oncology.
[7] P. Lønning,et al. Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series. , 2018, Anticancer research.
[8] R. Yaeger,et al. Colorectal cancer genomics and designing rational trials. , 2018, Annals of translational medicine.
[9] M. Choti,et al. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases , 2017, Annals of surgery.
[10] O. Lichtarge,et al. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases , 2017, Annals of surgery.
[11] J. Shindoh,et al. RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases , 2017, Annals of surgery.
[12] M. Kendrick,et al. Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. , 2017, The oncologist.
[13] Jesse S. Voss,et al. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Mountford,et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer , 2017, British Journal of Cancer.
[15] J. Vauthey,et al. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection , 2017, Surgery.
[16] Yuhree Kim,et al. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases , 2016, Cancer.
[17] T. Pawlik,et al. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. , 2016, Surgical oncology.
[18] V. Heinemann,et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] A. Russo,et al. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. , 2016, Critical reviews in oncology/hematology.
[20] M. Choti,et al. Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer , 2016, Annals of Surgical Oncology.
[21] J. Shindoh,et al. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion , 2016, Annals of Surgical Oncology.
[22] J. Vauthey,et al. Meta‐analysis of KRAS mutations and survival after resection of colorectal liver metastases , 2015, The British journal of surgery.
[23] M. Choti,et al. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. , 2015, JAMA surgery.
[24] V. Heinemann,et al. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. , 2015, Future oncology.
[25] G. Fontanini,et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] M. Choti,et al. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases , 2015, Annals of Surgical Oncology.
[27] M. Rugge,et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.
[28] M. D'Angelica,et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases , 2014, Cancer.
[29] M. Ladanyi,et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer , 2014, Cancer.
[30] Mef Nilbert,et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis , 2014, Acta oncologica.
[31] Steven A. Curley,et al. RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.
[32] D. Lambrechts,et al. Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab , 2013, Clinical Cancer Research.
[33] A. Viale,et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] P. Gibbs,et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.
[35] Roger Berry,et al. KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer , 2011, Clinical Cancer Research.
[36] A. Bardelli,et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.
[37] J. Neumann,et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. , 2009, Pathology, research and practice.
[38] T. Takada,et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. , 2004, Journal of hepato-biliary-pancreatic surgery.
[39] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[40] T. Starzl,et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. , 1999, Journal of the American College of Surgeons.
[41] B. Nordlinger,et al. Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.
[42] P. Lønning,et al. Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients. , 2019, Annals of surgery.
[43] I. Endo,et al. The Tumor Burden Score: A New “Metro-ticket” Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors , 2018, Annals of surgery.
[44] M. Gönen,et al. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. , 2018, Annals of surgery.
[45] Bradford J. Kim,et al. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter? , 2017, Annals of Surgical Oncology.